Physician profile
Mark E Lewis
NPI 1356322507
$2,180.94
in general payments reported to CMS, 2019-2025
30 companies · $371 in 2025
The $371 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $79.92 · 2021: $64.49 · 2022: $216 · 2023: $757 · 2024: $518 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,646.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $466.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $296.85 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $142.79 | 2022-2024 | Shingrix, Arexvy, Pediarix |
| Lilly USA, LLC | $136.11 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $119.73 | 2019-2023 | |
| Amgen INC. | $98.63 | 2019-2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $98.47 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $87.95 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $78.85 | 2024-2025 | Airsupra, Farxiga |
| E.R. Squibb & Sons, L.L.C. | $63.71 | 2019-2025 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.80 | 2024-2025 | Xifaxan |
| Abbvie INC. | $57.28 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.65 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Inspire Medical Systems, INC. | $52.46 | 2023-2024 | Inspire |
| Merck Sharp & Dohme LLC | $51.35 | 2023 | Verquvo, Belsomra, Steglatro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $35.36 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $33.84 | 2023 | Xarelto |
| Alexion Pharmaceuticals, INC. | $31.51 | 2024 | Ultomiris |
| Astellas Pharma US INC | $23.35 | 2022 | |
| Lundbeck LLC | $20.94 | 2024 | Rexulti |
| Biotissue Holdings INC. | $20.00 | 2021 | |
| Amarin Pharma, INC. | $19.80 | 2022 | |
| Corcept Therapeutics | $19.68 | 2025 | Korlym |
| Genentech USA, INC. | $19.43 | 2019 | |
| Shield Therapeutics INC | $18.85 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $17.48 | 2023 | |
| Viatris Specialty LLC | $15.77 | 2025 | Yupelri |
| Allergan, INC. | $13.69 | 2019 | |
| Dexcom, INC. | $13.68 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $13.51 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.